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Abstract
Background: Triple therapy including Telaprevir or Boceprevir still represents in many European countries the standard of
care for patients with Hepatitis C Virus genotype 1 infection. The number of patients who received this treatment resulted
generally lower than expected. We investigated, among naı¨ve patients, number and characteristics of treatment candidates
who were started on triple or dual therapy in comparison to those who were deferred.
Patients and Methods: 621 naı¨ve treatment candidates were prospectively evaluated at each center. Factors associated
with decision to defer or treat with dual or triple therapy were investigated by univariate and multivariate analyses. Rates of
Sustained Virological Response and safety profile were analysed.
Results: Of candidates to treatment, 33% did not received it. It was mostly due to high risk of Interferon-induced
decompensation. Of 397 patients who were started on treatment, 266 (67%) received triple, 131 dual. Among patient
receiving treatment, unfavorable IL28B, severe liver damage and higher albumin were independently associated with the
physician decision to administer triple therapy. Sustained Virological Response after dual therapy was 66.4%, after triple
73.7% (p = 0.14). 142 patients received Telaprevir. The choice of Telaprevir-based therapy was associated with higher Body
Mass Index and advanced liver disease. Sustained Virological Response rates were 71.1% after Telaprevir and 76.6% after
Boceprevir.
Conclusions: Individualizing treatment with available regimens allows to maximize Sustained Virological Response and to
reduce the number of patients who remain untreated. High proportion of patients with severe liver damage urgently need
Interferon free treatment.
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Introduction
Worldwide HCV infection affects more than 180 million people
[1]. In Italy, it is estimated that more than 1.4 million of people
carry the virus [2]. However, no more than 20% of patients with
advanced liver disease receive treatment [3]. Despite anticipated
esteems of high numbers of candidates, patients treated with triple
therapy (TT) including Telaprevir (TVR) or Boceprevir (BOC),
yet representing the standard of care for HCV genotype 1 in many
European countries, ranges from 44% to 49% of the expected
numbers [4,5]. In US, Chen et al showed that the rate of subjects
initiating TT (18.7%) was nearly identical to the treatment rate
reported with dual therapy (DT) [6]. In Europe, in a single center
study, half of treatment candidates were not started because of
safety concerns [5]. Both EU and US studies refer to a mixed
population of prior treatment failures and naı¨ve patients [4–6].
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The safety profile of the TT combination appeared poor.
Hospitalization during the first 12 weeks of treatment were
frequent with anemia being responsible for them in 65% of cases
[5,7]. In the CUPIC cohort focusing on patients with very
advanced liver disease, severe anemia was reported in 13% of
patients on TVR and in 9% of those on BOC. In the same cohort,
rash was associated with treatment discontinuation in 5.3% of
patients receiving TVR [8]. However, the occurrence of side
effects seems to be lower in previously untreated patients, as
anemia rates ,8.5 g/dL were registered in 5–9% in the SPRINT-
2 study and in 4% in the ADVANCE [9,10] in comparison to 14%
in RESPOND and REALIZE [11,12].
Beside of side effects, other factors limited the proportion of
patients receiving triple combination treatment. Indeed, candidacy
to TT was largely debated at a country level due to the complexity
of the regimens. In Italy, additional reasons for barrier to
treatment were represented by treating centers selection: only
some centers were allowed to perform TT on the basis of
predefined skills and on the availability of specific tools that
include a quick turn-around for HCV RNA assays results, IL28B
genetic testing and availability of transient elastometry. Moreover,
Italian Guidelines advised treatment of naı¨ve or treatment
experienced patients with advanced fibrosis and cirrhosis, but at
a local level some regions decided to select for TT regimens only
patients with a prior treatment failure [13]. Finally, it was
suggested that a proportion of patients with favorable baseline
factors may continue to be treated with dual therapy to spare
economical resources in consideration of the higher costs of DAA
[14].
At this stage it remains unclear what proportion of the total
HCV genotype 1 naı¨ve patients eligible to triple therapy took
advantage of TT in the real world. With the more convenient
safety profile of the coming interferon free regimens it may be
interesting to clarify whether reasons not to initiate therapy are
related to the presence of a mild disease or to poor chances of
achieving SVR due to high risk of side effects or because of
coexistence of unfavorable baseline predictors [15,16]. The main
goal of this analysis is to prospectively evaluate physicians
preferences on treatment decision in our country, in naı¨ve
genotype 1 patients followed at different centers. Secondary
objectives were to assess the virologic response to TT in naı¨ve
patients, in a real world experience.
Patients and Methods
This study was a non interventional prospective nationwide
multicenter cohort study conducted at 22 Italian centers since June
2012, when the genetic samples of candidate naı¨ve patients with
HCV genotype 1 infection were centralized and tested. Patients
with decompensated cirrhosis in Child-Pugh class $B7 were not
included. Screening started on January and enrollment on
February 2013 when TT become available in Italy. Only patients
who completed 12 week of follow up by May 2014 are included in
this analysis. Patients with history of previous treatments, as well as
patients with HIV or HBV co-infection, were not eligible.
Diagnosis of cirrhosis was made by liver biopsy or by non invasive
test, transient elastometry or APRI. Written informed consent was
obtained for the participation in the perspective study as a whole.
The protocol was conducted in accordance with the Declaration of
Helsinki and was approved by the coordinating center’s Ethic
Committee (Independent Ethic Committee –IEC–, IRCCS ‘‘Casa
Sollievo della Sofferenza’’).
As the aim of the study was to obtain a picture of physician
behavior in the real life, treatment or deferral decision were made
individually by the physician in charge and were not influenced by
a common protocol. All naı¨ve patients consecutively observed
were included. TT with both first generation protease inhibitors
(PI), TVR or BOC was allowed. Patients were monitored
according to physician preference but a minimum of twice a
month visit and laboratory evaluation was performed at each
center.
Anemia was graded as severe when Hb levels were 9 g/L,
neutropenia when neutrophil count lower than 800 cells/mm3 was
registered. Treatment was discontinued when Hb levels were ,
8.0 g/L without improvement after ribavirin dose reduction and
blood transfusion. Granulocyte colony stimulating factors were not
admitted and neutropenia was managed by PegInterferon dose
reduction.
Treatment
DT and TT were prescribed in accordance with the National
guidelines and stopping rules [13]. For TT, response guided
therapy was adopted in non cirrhotic patients, while cirrhotic
received 48 weeks of treatment.
HCV RNA monitoring
HCV RNA levels were measured at baseline and at weeks 4, 8,
12, 16, 24, 36, and 48 during treatment, and 12 and 24 weeks off
treatment, by a real-time PCR based assay, either COBAS
AmpliPrep/COBAS TaqMan (Roche Molecular Systems, Plea-
santon, California) with a lower limit of detection of 15 IU/ml, or
m2000 SP/m2000 RT (Abbott Molecular, Des Moines, Illinois),
with a lower limit of detection of 12 IU/ml. In this analysis,
virological responses at week 12 after treatment were evaluated.
Non cirrhotic patients with eRVR defined as undetectable HCV
RNA result at week 4 and 24 in TVR arm and patients
undetectable at week 8 and 24 on BOC arm received a course of
treatment of 24 weeks only. Stopping rules were used in
accordance with Italian guidelines [13].
IL28B genotype
IL28B genotyping (rs1297860) was centralized (Liver Unit,
IRCCS San Giovanni Rotondo). Genotype was determined for all
patients candidate to treatment. Patients DNA were extracted
from peripheral blood using standard methods. Genotyping was
performed using TaqMan allelic discrimination assay, as described
[17]. Hardy-Weinberg’s equilibrium of the IL28B polymorphism
was tested for the study population.
Fibrosis assessment
Fibrosis staging was defined by liver histology according to
Scheuer’s classification in 36% of subjects [18]. All the patients
received a non invasive evaluation including transient elastometry
using the threshold of 12.5 KPa to define cirrhosis or biomarkers.
The biomarker used was APRI. The threshold used to define
cirrhosis by APRI was $2.
Statistical analysis
Data are presented as percentages for categorical variables and
mean with standard deviations for continuous variables. Univar-
iate analyses of baseline or pretreatment variables were performed
by two-sided t test and chi squared with Fisher’s exact test when
appropriate. Within-group, comparisons were made using the
Wilcoxon test. Baseline variables with P values #0.05 by
univariate analyses entered into multivariate logistic regression
model to find independent factors, which were expressed by Odds
ratio (OR) with 95% confidence intervals (95% CI) for predictors
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of different of physician decisions or treatment responses.
Backward elimination procedure was used. Statistical analysis
was performed by SPSS version 10.0 (SPSS, Chicago IL). Median
values of quantitative variables were compared using a nonpara-
metric test (Mann-Withney two-tailed test).
Efficacy analyses were performed on an intent-to-treat basis.




Among 621 consecutive patients with chronic HCV genotype 1
infection who were referred to the 22 outpatients clinics involved
in this study, we restricted the analysis to the 587 patients who did
not enter clinical trials ongoing in the same period of time at 4 out
of 22 participating centers (Fig. 1). Baseline characteristics of
patients overall and by treatment or deferral decision are shown in
Table 1.
Patients treated versus patients deferred
Overall 397 (67%) naı¨ve patients aged .18 were treated while
the remaining 190 were not (Fig. 1). Therefore, in our country, a
consistent proportion of patients with HCV genotype 1 evaluated
for treatment did not receive any of the currently available
therapies. Of patients who were started on therapy, 62% were
male, while a higher proportion of female was observed among
untreated patients. A favorable IL28B profile was observed at
comparable frequency between treated and untreated patients.
Among treatment candidates, genotype 1b was identified in 62%,
genotype 1a, in 25%. In the remaining, subtypes were undeter-
mined. HCV RNA levels were not associated with the decision of
treating or not. Among untreated patients, rates of ALT were
lower. Overall, advanced fibrosis or cirrhosis, as defined by
elastometry, was present in 151 subjects (38.0%) undergoing
treatment. The proportion of patients with cirrhosis was higher in
treated than in untreated (21.5%). This evidence suggests that
physician’s decision to treat or not was mostly driven by reasons
related to the urgency of treatment determined by an advanced
liver damage. However, this liver damage had to be not at risk of
decompensation because when baseline Hb, albumin levels and
PLT counts were investigated, as shown in Table 1, low PLT
counts and albumin levels were significantly associated with
decision not to treat (p = 0.001 and p= 0.0001, respectively).
Consistently, APRI score $2 was observed at significantly higher
proportion in patients untreated as compared to treated (41.9% vs
32.1%). These findings suggest that evidence of advanced liver
damage associated with low risk of decompensation rather than
favorable predictors of response oriented physician choices.
Independent predictors of treatment resulted higher albumin
levels OR=0.79; 95% CI 0.67–0.93 (p= 0.005) and IL28BCC
OR=0.54; 95% CI 0.34–0.83 (p= 0.01).
Characteristics of patients receiving treatment: dual
versus triple therapy
Of 397 patients who were treated, 266 (67.0%) received TT,
while the remaining 131 initiated dual therapy (Fig. 1). Baseline
factors associated with the choice of DT or TT are reported in
Table 2. Of patients who started TT, the proportion of male, was
comparable with that of subjects candidate to DT. Mean age of
patients initiating TT was higher than mean age of patients
initiating DT (p= 0.02). In the group of TT, 34.6% of patients had
diagnosis of cirrhosis, this percentage was significantly higher than
the corresponding 13.6% rate observed in patients receiving DT
(p= 0.0001). Mean PLT count was lower among patients receiving
TT than among those receiving DT (p= 0.0001). No difference in
HCV subtype distribution was observed. In addition to older age,
severe liver disease, proven also by baseline PLT counts, IL28BCC
genotype was differently distributed between the two treatment
groups. Indeed, we observed an association between CC and dual
therapy (p = 0.0001). Higher albumin levels were observed among
patients receiving TT as compared to DT (p= 0.0001).
As shown in Fig. 2 in patients with IL28B non-CC and
cirrhosis, the addition of PI increased SVR rates.
By multivariate analysis, independent predictors associated with
the choice of triple therapy were severe liver damage OR=1.4,
95% CI 1.06–1.86 (p = 0.018), IL28B non-CC OR=2.45, 95%
CI 1.35–4.46, (p = 0.004) and higher albumin levels OR=1.89,
95% CI 1.28–2.80 (p = 0.001).
Efficacy of therapy: dual versus triple therapy
In intent-to-treat analysis, among the 131 naı¨ve patients who
received DT, HCV RNA was undetectable at 12 weeks of follow
up in 87 (66.4%) (95% CI: 58.3–74.5). The corresponding rate
among 266 naı¨ve patients receiving TT was 74.0% (95% CI:
68.7–79.3). Eight and 5 patients experienced a relapse with DT
therapy or TT, respectively (p = 0.16). Of interest, in 33 of 174
patients without cirrhosis who received TT it was possible to
administer a short course of TT in accordance with eRVR.
Relapse was registered in 12.5% of patients. Factors independently
associated with SVR to TT were investigated by uni and
multivariate analysis including TVR or BOC as covariate. Higher
proportion of patients with advanced liver damage was registered
among non responders as compared to responder patient 47.1% vs
25.5% (p= 0.001). IL28BCC was observed in 28% of responders
as compared to 11.6% of non responders (p = 0.008) (Fig. 2).
Multivariate analysis confirmed IL28BCC as the independent
predictor OR=0.34, 95% CI 0.14–0.83 (p= 0.018).
Discontinuation rate was lower than reported in other real life
studies, as 23 of 266 patient on TT (8.7%) and 7 of 131 on DT
(5.3%) discontinued due to side effects. Among patients who were
treated with TT, all the discontinuations were due to side effects,
while among patients receiving DT, only 2 of 6 discontinued due
to side effects. The rate of patients developing anemia during
treatment was 22.2% for DT and 39% for TT (p= 0.24). Only 5%
on DT versus 21% of patients on TT required blood transfusion
(p = 0.26). Neutropenia was registered in 11.1% of patients on DT
and in 22% of patients on TT (p= 0.46). No cutaneous rash was
observed among patients on DT, the corresponding rate was
14.2% among patients receiving TT (p= 0.15).
Of patients receiving TT, 13 discontinued TVR and 9
discontinued BOC; it was due to adverse events, represented by
anemia in 2 cases receiving TVR, rash/pruritus of moderate grade
in 4, and Dress syndrome in 1. Severe neutropenia and
thrombocytopenia were associated with the remaining patients.
For patients receiving BOC, 6 cases of pneumonia required
treatment discontinuation and hospitalization, 1 patient had severe
neutropenia. Other reasons for treatment discontinuation included
generic intolerance.
Characteristics of patients receiving TVR or BOC based
triple therapy
Of 266 patients who received triple therapy, 142 (53.3%) were
treated with TVR and 124 (46.7%) with BOC-based combination.
In order to understand reasons for physicians preferences, baseline
characteristics of patients enrolled to BOC were compared with
those of patients enrolled to TVR (Table 3). As shown, in the latter
group significantly higher number of patients had higher mean
Triple Therapy in Real Life
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BMI (25.9 vs 22.8, p = 0.001) and low PLT count (143671 versus
182675, p = 0.0001). By contrast, in the former group, higher
proportion of patients had less advanced liver damage
(p = 0.0001). No differences were observed in the distribution of
HCV subtypes, IL28B genotypes, APRI score and albumin,
between the two treatments. Notably, no difference in the rate of
treatment discontinuation by different PI were registered. At
multivariate analysis, the factors independently associated with
physician preferences for TVR resulted higher BMI (OR=0.91;
95% CI 0.87– 0.95 p= 0.001), cirrhosis (OR=0.66; 95% CI 0.48–
0.91 p= 0.013) and PLT count (OR=1.01; 95% CI 1.00–1.02
p= 0.001).
Head to head comparison of the two treatment regimens was
not aim of this study, nevertheless, we observed that rates of SVR
between triple therapies including BOC or TVR are comparable
(71% vs 77%; 95% CI: 63–79 and 70–84, respectively). To
understand whether unfavorable baseline factors identified
according to physician’s preferences in each treatment might have
impaired rates of SVR in TVR group, we performed adjustments
for cirrhosis and BMI in a further analysis of predictors of SVR,
considering TVR as the selection variable. BMI and cirrhosis were
not independent predictors of SVR.
Discussion
The recently released European guidelines for the treatment of
hepatitis C state that, when newer therapy options are not
available, a first generation PI in combination with Peg-IFN and
RBV represents the first option for treatment of genotype 1
infected patients [14]. Given the diversity of European population
and reimbursement practices, these recommendations differ from
those released in US that did not recommend the use of first
generation PI [19]. Until recently, TVR and BOC were evaluated
mostly in clinical trials. Data on efficacy and safety in real life are
derived from the CUPIC study that was performed to explore
applicability of this combination in previously treated patients with
very advanced liver disease [8] and from the large German PAN
cohort whose SVR is not yet available [20]. This is a ‘‘real world’’
multicenter non interventional study, representative of Italian
physician behavior and treatment decision in newly diagnosed
patients. The study focus on patients seeking treatment who were
firstly seen at 22 different Italian centers. Our results suggest that
in naı¨ve patients Italian physicians decided to defer treatment in
32% of cases. This rate would have been much higher if instead of
not treating Italian physician would not have used the standard
dual combination in 22% of treatment candidates. As a
consequence, rather than 54%, only 32% of patients remained
untreated. Of patients who were not treated, no more than 60%
had mild or moderate fibrosis and significantly higher PLT count
suggesting evidence of a mild disease. As patients with Child-Pugh
$B7 were excluded from this study, involving only previously
untreated patients, we assumed that reasons not to treat would
have been an initial disease in the vast majority of cases, yet 15 of
37 patients with PLT count below 100.000/mL and albumin ,
3.5 mg/dl (40%) remained untreated, among naı¨ve patients. For
these patients IFN free options are urgently needed [21,22].
Selecting for Peg-IFN and ribavirin therapy, 22% genotype 1
naı¨ve patients with favorable baseline characteristics resulted in a
more effective strategy than allowing liver disease to progress
without treatment in waiting to have access to new DAA. In this
respect, our results partially differ from those attained a few
months ago in another real life study where 60% of patients
Figure 1. Patient disposition in the study.
doi:10.1371/journal.pone.0110284.g001
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Table 1. Characteristics of naı¨ve candidate patients by physician decision to treat or not.
Characteristics Pts treated N=397 (67.6) Pts deferred N=190 (32.4) P Value
Male, no (%) 246 (62.0) 97 (51.1) 0.01
Mean age 6SD (yrs) 54.0612.7 53.1614.3 0.44
Mean BMI6SD (Kg/m2) 24.769.0 23.869.5 0.10
HCV genotype, no (%)
1 50 (12.5) 19 (10.0)
1a 100 (25.2) 46 (24.2) 0.68
1b 247 (62.3) 125 (65.8)
Mean baseline HCV RNA x 106 IU/mL6SD 3.061.2 2.062.9 0.26
Mean ALT IU/L6SD 87.5666.3 69.0655.8 0.001
Mean platelet count x 103/mL6SD 180668 202673 0.0001
rs12979860 genotype frequency*
IL28B carriers CC, no (%) 95 (27.1) 36 (18.9)
IL28B carriers CT, no (%) 196 (53.1) 121 (63.7) 0.12
IL28B carriers TT, no (%) 60 (16.9) 33 (17.4)
Cirrhosis ($12.5 KPa) no (%) 110 (27.8) 41 (21.5) 0.14
APRI score $216SD 120 (32.1) 80 (41.9) 0.02
Baseline Hb g/dL6SD 13.968.1 12.864.3 0.06
Baseline Albumin g/dL6SD 3.960.9 3.461.5 0.0001
*IL28B rs12979860 undetermined in 47 cases among treated patients; 1 not available in 22 cases among treated patients.
doi:10.1371/journal.pone.0110284.t001
Table 2. Characteristics of patients treated with triple or dual combination.
Characteristics Pts receiving triple Tx Pts receiving dual Tx P Value
N=266 (67.0) N=131 (33.0)
Male, no (%) 169 (63.5) 75 (57.3) 0.27
Mean age 6SD (yrs) 55.1612.5 51.9613.0 0.021
Mean BMI 6SD (kg/m2) 35.8615.6 22.8631.1 0.46
HCV genotype, no (%)
1 26 (9.9) 23 (17.6)
1a 75 (28.6) 24 (18.3) 0.021
1b 164 (61.5) 83 (63.4)
Mean baseline HCV RNA x 106 IU/mL6SD 3.661.6 2.363.1 0.34
Mean ALT IU/L6SD 84.763.8 89.366.5 0.52
Mean platelet count X103/mL6SD 162676 203676 0.0001
rs12979860 genotype frequency*
IL28B carriers CC, no (%) 49 (24.0) 46 (36.8)
IL28B carriers CT, no (%) 135 (57.8) 61 (48.8) 0.016
IL28B carriers TT, no (%) 42 (18.2) 18 (14.4)
Cirrhosis ($12.5 KPa), no (%) 92 (34.6) 18 (13.6) 0.0001
APRI score $216SD 77 (31.6) 43 (32.8) 0.89
Baseline Hb g/dL6SD 13.464.6 14.9612.3 0.07
Baseline Albumin g/dL6SD 4.160.7 3.660.1 0.0001
SVR, no (%) 197 (74.0) 87 (66.4) 0.14
*IL28B rs12979860 undetermined in 41 and 6 patients treated with TT or DT, respectively;
1not available in 22 cases among patients receiving TT.
doi:10.1371/journal.pone.0110284.t002
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candidate to TT were treatment experienced [5]. In that study,
higher proportion of patients remained untreated. The decision to
defer treatment was based on treatment related safety concerns in
64% of cases and on patients preferences in 32%. In this study of
151 patients with cirrhosis, 60% received TT, 23% remained
untreated and 12% received DT. The decision not to treat was
Figure 2. Association between SVR and IL28B genotype. All treated patients (gray) or patients receiving triple therapy (white) were analysed
by cirrhosis status and IL28 CC or non CC.
doi:10.1371/journal.pone.0110284.g002
Table 3. Baseline factors orienting physician choices FOR TVR or BOC.
Characteristics Pts receiving TVR Pts receiving BOC P Value
N=142 (53.3) N=124 (46.7)
Male, no (%) 98 (69.0) 75 (60.5) 0.22
Mean age 6SD (yrs) 55.6610.7 54.4614.3 0.44
Mean BMI6SD (kg/m2) 25.966.4 22.868.5 0.001
HCV genotype, no (%)
1 16 (11.4) 10 (8.1)
1a 42 (29.3) 34 (27.1) 0.71
1b 84 (59.3) 83 (63.4)
HCV RNA x 106 IU/mL6SD 4.462.0 2.363.0 0.26
Mean ALT IU/L6SD 92.0662.9 80.1660.4 0.13
Mean platelet count x 103/mL6SD 143671 182675 0.0001
rs12979860 genotype frequency*
IL28B carriers CC, no (%) 23 (22.3) 26 (24.2)
IL28B carriers CT, no (%) 64 (62.1) 71 (54.8) 0.67
IL28B carriers TT, no (%) 16 (15.6) 26 (21.0)
Cirrhosis ($12.5 KPa) no (%) 66 (46.5) 26 (21.0) 0.0001
APRI score $216SD 42 (32.5) 35 (30.4) 0.82
Baseline Hb g/dL6SD 13.265.0 13.763.9 0.91
Albumin g/dL6SD 4.160.4 4.060.6 0.46
*IL28B rs12979860 undetermined in 40 patients treated with TVR and 1 treated with BOC; 1not available in 13 cases among patients treated with TVR and in 9 patients
treated with BOC
doi:10.1371/journal.pone.0110284.t003
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based on safety in 50% of cases, while, due to the different
characteristics of the studies, in the remaining cases it was
dependent on the presence of mild liver damage.
The need of adding a third drug to Peg-IFN and RBV, in real
life, appears challenging in patients with baseline unfavorable
characteristics. Indeed, among 266 patients who received TT, the
final decision to start this regimen instead of DT was supported by
two independent predictors: an unfavorable IL28B profile and an
advanced liver damage in the absence of risk of decompensation.
As a consequence of this selection for treatment candidates to DT
over TT, 66% rates of SVR registered after DT were higher than
those traditionally reported in genotype 1 after Peg-IFN and
ribavirin [23,24]. On the other hand, despite the unfavorable
IL28B profile, considering that patients with high risk of
decompensation were excluded, among patients receiving TT
SVR rates registered in this study are absolutely comparable to the
response rates reported in registration trials on TT, in naı¨ve
patients [9,10]. When compared to other real life studies not
focusing on CUPIC-like patient population [25], rates of SVR in
our study were similar. A 63.4% SVR response rate was observed
in PAN cohort including 273 naı¨ve patients receiving TVR [20].
However, missing information on liver disease assessment from
that study prevent any comparison. In the same cohort, 85 naı¨ve
patients receiving BOC achieved on treatment response of 71.6%
at week 12. In our study SVR rate for patients receiving BOC was
comparable with this on treatment rate, although since no SVR
results are currently available from that cohort, conclusions cannot
be driven.
In this study, patients candidate to TVR based regimen had
higher BMI and more advanced liver damage. Of course this is not
a randomized controlled study and selection bias cannot certainly
be ruled out. As the study was not aimed to an head to head
comparison, we cannot reach conclusions on the different efficacy
of the different TT combination.
As high incidence of side effects has been so far demonstrated
using first generation PI, mostly in patients who were treatment
experienced, we investigated how this treatment was tolerated in
naı¨ve patients, in real life. We observed that, carefully monitoring
patients every 4 weeks during the initial 12 week treatment period,
the risk of discontinuation is low and comparable to that of
patients receiving DT. Indeed, the rate of discontinuation in
patients receiving TT in this study was relatively low, although in
every patient, treatment withdrawal was due to side effects in
particular to severe anemia, thrombocytopenia or pulmonary
infections. These findings are in keeping with other studies
suggesting for example that the proportion of patients requiring
hospitalization during the first 12 weeks of TT was significantly
lower among naı¨ve as compared to treatment experienced [5].
The main quality of the present study is that it is reasonably
representative of the real life experience with triple therapy in
Italy. Firstly, the proportion of academic and not- academic
centers in this study reflects the results of a recent survey of the
Italian association for Liver Study (AISF) on centers working on
the field of Liver Diseases in Italy where, of the about 200 centers
censored, 30% were academic while the remaining were not.
Moreover, because the centers who took part in this study were
recruited in North, Centre and South Italy and either regions
whose administration allowed triple treatment only in patients
with advanced diseases, or regions who allowed treatment
irrespective of disease severity were included. Although the sample
size of our study is not large, we can provide virological results of
the entire treatment and follow up for each patient.
With the approach preferred by Italian physicians, high rate of
patients with advanced disease, yet did not receive treatment. In
order to solve this issue newer IFN-free treatment regimens will
ensure higher adherence and treatment suitability in patients with
risk of cirrhosis decompensation.
In conclusion, the individualized strategy, adopted by Italian
physician in naı¨ve genotype 1 patients, allows larger number of
patients to be treated and maximizes responses rates.
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